In this episode of Pharma Sessions, host Jonathan Kaskey interviews Dr. Huma Qamar, Head of Clinical Development and Medical Affairs at Ocugen, Inc.
With her extensive background in clinical research and medicine, Dr. Qamar has been a pioneer in merging these two fields. Throughout this episode, she shares her invaluable insights on gene therapy, specifically focusing on inherited retinal diseases. Here are the top five things you'll learn:
1. The importance of patient-centered outcomes research and the different phases of clinical trials.
2. The challenges and advancements in developing gene therapies for unmet medical needs.
3. How to navigate the regulatory landscape of gene therapy and the role of the FDA in this process.
4. The significance of patient-reported outcomes and how they impact clinical development and medical affairs.
5. The future of gene therapy, including its potential to revolutionize healthcare and improve patients' quality of life.
Subscribe to the PharmaSessions substack for exclusive content and show updates: www.pharmasessions.substack.com
Pharma Sessions is hosted by Jonathan Kaskey
Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/
Or join the Pharma Sessions Substack:
www.pharmasessions.substack.com